N/A
N=94
Building Resiliency Among Caregivers of Curvivors and Metavivors
Stress · Cancer Diagnosis · Distress, Emotional
Bottom Line
View on ClinicalTrials.gov: NCT05702723 ↗Enrolled (actual)
94
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Proportion of Enrolled Participants (Feasibility) — 94 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Smart-3RP (Behavioral); Enhanced Usual Care (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Massachusetts General Hospital
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Enrolled Participants (Feasibility) |
94 | — |
| PRIMARY Proportion of Intervention Satisfaction (Acceptability) |
31 | — |
| SECONDARY Proportion of Study Retention (Feasibility) |
39; 37 | — |
| SECONDARY Proportion of Intervention Session Completion (Feasibility) |
36 | — |
Summary
The main purpose of this research study is to assess the feasibility and participants' satisfaction of the Stress Management and Resiliency - Relaxation Response Resiliency Program (SMART-3RP) and compare this treatment with SMART-3RP versus referral to a group-based, online support group to see which is better for improving resilience and decreasing distress of participants with cancer and their caregivers.
The name of the study intervention involved in this study is:
Smart-3RP (virtual, mind-body group treatment program).
Eligibility Criteria
Inclusion Criteria for Patients:
- English speaking adult patients with cancer (18 years or older)
- Treated at MGH, who are either within approximately:
- 3 months to 3 years after completing potentially curative therapy for cancer diagnosis including surgery, radiation, and/or chemotherapy or other novel therapies (e.g., immunotherapy, biological therapy). Patients can be on long- term maintenance hormonal or biological therapy at the time of enrollment.
- 3 months after diagnosis of metastatic disease with an expected prognosis of >1 year as confirmed by the treating oncology clinician
- Able to identify a caregiver (i.e., spouse/partner or patient-identified family member or friend) who is willing to participate in the study
Exclusion Criteria for Patients:
- Prognosis less than one year as determined by the treating oncology clinician
- Active psychiatric or cognitive comorbidity that prohibits the capacity to provide informed consent as determined by the treating oncology clinician
- Patients without a caregiver who is willing to participate
Inclusion Criteria for Caregivers:
- Adult caregiver (age 18 years or older).
- Identified by the patient as the spouse/partner or family member/friend.
Data sourced from ClinicalTrials.gov (NCT05702723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.